Avalyn Pharma Inc. Common Stock
NASDAQ:AVLNMedical - Pharmaceuticals
+$0.52 today
- Market cap
- $1.23B
- Beta
- 0.00
Volume 0.40M
Average 0.51M
AVLN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Research & Development history
Currency unavailable · from the income statement
No Research & Development data reported for this period type.
Research & Development vs competitors
How AVLN compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $860.85M USD | +30.4% | +24.7% | 75.7% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 238.42M SEK | +2.0% | +16.0% | 17927.0% |
| LTM Mar 2026 | $72.56M USD | +54.7% | +49.8% | 20.1% | |
| LTM Mar 2026 | $17.34M USD | +34.0% | -6.4% | 14.8% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding AVLN) | — | +32.2% | +20.4% | 47.9% | |
Competitors are the stored peer set for AVLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Avalyn Pharma Inc. Common Stock
NASDAQ:AVLN
Intrinsic Alpha fair value
Locked
Current Price
$27.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.